U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416682) titled 'CAR BCMA-70 CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms' on Feb. 11.
Brief Summary: This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Plasma Cell Neoplasms
Intervention:
GENETIC: CAR BCMA-CD70-T cells
CAR BCMA-CD70-T cells Each subject will be infused with single dose of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation will be employed. The low dose is 1x10^6 /kg, the medium dose is 2x10^6 /kg, and...